Mizuho Securities Sticks to Its Hold Rating for Adamas Pharmaceuticals (ADMS)

By Carrie Williams

In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Hold rating on Adamas Pharmaceuticals (ADMSResearch Report), with a price target of $11. The company’s shares opened today at $9.30, close to its 52-week low of $7.42.

Rivkind Koffler noted:

“We see minimal 2019 catalysts or take-out possibility for Adamas, and reiterate our Neutral rating. We also believe the stock will be pressured by the recent launch of Osmolex ER. We updated our model following guidance on 2019 Gocovri growth and a 7.75% price increase, with no change to our $11 PT.”

According to TipRanks.com, Koffler is a 4-star analyst with an average return of 5.2% and a 40.5% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Assertio Therapeutics Inc, and Eagle Pharmaceuticals Inc.

Adamas Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $27.

See today’s analyst top recommended stocks >>

The company has a one-year high of $44 and a one-year low of $7.42. Currently, Adamas Pharmaceuticals has an average volume of 666K.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ADMS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products includes ADS-5012, ADS-4101, and Namenda XR. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson’s disease.